First Affiliated Hospital of Zhejiang University School of Medicine, China
Author Profile
Early Academic Pursuits
Qi Zhang began his academic journey with a Bachelor of Biotechnology from the Academy of Life Science, Chu Kochen Honors College, Zhejiang University, under the supervision of Jizeng Du. He then pursued a Doctor of Clinical Medicine degree at Zhejiang University, guided by Supervisor Tingbo Liang. These formative years laid the groundwork for his subsequent specialization in hepatobiliary and pancreatic surgery.
Professional Endeavors
His professional trajectory showcases a commitment to excellence and continuous growth. He started as a Resident Physician at the Second Affiliated Hospital, Zhejiang University School of Medicine, before advancing to roles like Attending Doctor, Postdoctoral Fellow at the National Institutes of Health, and eventually rising to his current positions of Associate Professor and Associate Chief Physician of Hepatobiliary and Pancreatic Surgery at the First Affiliated Hospital, Zhejiang University School of Medicine.
Contributions and Research Focus
His research primarily revolves around hepatobiliary and pancreatic tumors. He has a multifaceted approach, encompassing clinical diagnosis and treatment, translational research, and basic science. Notably, his work delves into understanding the immune microenvironment of these tumors, developing innovative therapies, and elucidating the molecular mechanisms underlying their occurrence and progression.
Accolades and Recognition
His contributions have been widely recognized, evident from the numerous awards and honors he has received. Noteworthy among these are the Science Fund for Distinguished Young Scholars of Zhejiang Province and various first prizes from the People's Government of Zhejiang Province and the Zhejiang Provincial Health Commission. His research on the immune escape mechanism of hepatocellular carcinoma and key technologies for the diagnosis and treatment of pancreatic diseases has earned him acclaim.
Impact and Influence
His impact extends beyond his research contributions. He serves on the editorial boards of prestigious journals, indicating his standing in the scientific community. Moreover, his involvement in various professional committees and associations underscores his influence in shaping the discourse and direction of research in his field.
Legacy and Future Contributions
His legacy lies in his comprehensive approach to tackling hepatobiliary and pancreatic tumors, bridging clinical practice with cutting-edge research. His work not only advances scientific understanding but also directly impacts patient care through innovative treatment modalities. Looking forward, Zhang's continued dedication to excellence promises further breakthroughs in the diagnosis, treatment, and understanding of these challenging malignancies.
A total ofĀ 4302 citations for his publications, demonstrating the impact and recognition of his research within the academic community.
- CitationsĀ Ā Ā Ā Ā Ā Ā 4302
- h-indexĀ Ā Ā Ā Ā Ā Ā Ā 36
- DocumentsĀ Ā Ā Ā 132
Notable PublicationsĀ
Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study
Cell of Origin of Pancreatic cancer: Novel Findings and Current Understanding
Pan-Cancer Single-Nucleus Total RNA Sequencing Using snHH-Seq
Bacteria Synergized with PD-1 Blockade Enhance Positive Feedback Loop of Cancer Cells-M1 Macrophages-T Cells in Glioma
Large-scale pancreatic cancer detection via non-contrast CT and deep learning
Correction: Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients (Clinical Epigenetics,Ā
Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation
Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients
Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cases
ASO Visual Abstract: Low-Pass Genomic Sequencing Reveals Novel Subtypes of Pancreatic Cystic Neoplasms